{"publication_id":"43509a3d-2c33-48fb-9e4f-c3802c27d437","screening":{"identified":16,"screened":16,"excluded":0,"included":16,"included_or_retained":16,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that nad biomarker effects should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","Population aging is accelerating worldwide, yet the biology of aging itself has only recently been proposed as a tractable therapeutic target. The central clinical question is whether interventions that slow or partially reverse fundamental aging processes can extend healthspan—the period of life spent free from chronic disease and functional disability. This question carries enormous stakes: even modest delays in the onset of age-related multimorbidity could transform healthcare economics and quality of life for hundreds of millions of people. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme central to cellular energy metabolism whose levels appear to decline with age across multiple tissues. Nad Biomarker Effects—the pharmacological restoration of NAD+ through precursor supplementation—has therefore attracted intense scientific and popular attention as a potential anti-aging strategy. However, the evidence base for Nad Biomarker Effects remains fragmented across heterogeneous outcome domains, populations, and study designs, creating an urgent need for structured synthesis.","The geroscience hypothesis posits that because aging is the dominant risk factor for most chronic diseases, targeting fundamental aging biology may be more efficient than treating individual diseases in isolation. This framework has motivated the repurposing of existing pharmacological agents—such as metformin, rapamycin, and NAD+ precursors—that appear to modulate conserved longevity pathways. Nad Biomarker Effects fits squarely within this logic: if declining NAD+ availability drives cellular dysfunction across organ systems, then restoring NAD+ levels could simultaneously attenuate multiple age-related pathologies. The appeal of NAD+ precursors is partly pragmatic: compounds like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are available as dietary supplements, enabling consumer access without formal regulatory approval for disease indications. Yet this very accessibility has created a disconnect between widespread public use and the limited clinical trial evidence that exists. Whether Nad Biomarker Effects can fulfill the promise of the geroscience hypothesis depends on translating mechanistic plausibility into demonstrable human benefit across diverse clinical endpoints.","Several unresolved questions cloud the translational trajectory of Nad Biomarker Effects. First, the mechanistic link between elevated NAD+ and functional improvement appears to be context-dependent: preclinical models show benefit in specific conditions such as LPS-induced inflammation via the TLR4/NF-κB pathway (Ahmed 2024) and ischemia-reperfusion injury under certain anesthetic conditions (Xiao 2021), yet these findings have not reliably translated to human outcomes. Second, dose-response relationships for NAD+ precursors remain poorly characterized, with trials employing doses ranging from 250 mg to 1,000 mg daily of NR without systematic comparison. Third, population specificity is a major concern: most human trials have enrolled relatively healthy older adults, leaving open the question of whether Nad Biomarker Effects might benefit frailer populations such as those with sarcopenia, where Membrez et al. identified reduced levels of the NAD+ precursor trigonelline. Fourth, trial durations have generally been short—typically 14 to 21 days—and it remains unknown whether longer supplementation periods would yield more robust clinical effects or whether chronic use carries unrecognized risks. Finally, the interplay between NAD+ metabolism and the broader microbiome, as explored by Christen et al. and Wu et al., suggests that Nad Biomarker Effects may have systemic consequences that extend beyond direct tissue NAD+ repletion.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","The evidence base for NAD⁺ precursor supplementation on cardiometabolic outcomes includes a randomized, placebo-controlled, crossover clinical trial in healthy middle-aged and older adults (Martens 2018) and systematic reviews synthesizing data from physically compromised older adults (NAD 2021) and broader adult populations (Diaz-Urbina 2026). Martens 2018 administered nicotinamide riboside (NR) at 500 mg twice daily and reported that chronic supplementation was well-tolerated and elevated NAD⁺ levels (Martens 2018). However, a systematic review by NAD 2021 evaluating NAD⁺-precursor supplementation with L-tryptophan, nicotinic acid, and nicotinamide in physically compromised older adults reported that mitochondrial function and skeletal muscle function were not affected (NAD 2021). Specifically, ADP-stimulated respiration showed no significant difference between intervention and control groups (82.1 ± 19.0 vs. 84.0 ± 19.2; P = 0.716) (NAD 2021). Further analyses within this review yielded non-significant results for related cardiometabolic parameters (P = 0.495, P = 0.342) (NAD 2021).","The tension within this outcome class is characterized by a directional disagreement between studies that report clear biomarker modulation and some endpoint improvements (Martens 2018) and those that find no significant functional effect on mitochondrial parameters despite precursor supplementation (NAD 2021). Conversely, NAD 2021 found no effect on ADP-stimulated mitochondrial respiration (P = 0.716) or other skeletal muscle functional measures (P = 0.495, P = 0.342) in physically compromised older adults (NAD 2021). This disagreement is non-orthogonal because both studies address NAD⁺ precursor effects in older adult populations but differ in the specific precursor used, the population's health status, and the endpoints measured (Martens 2018, NAD 2021). The preclinical evidence from Diaz-Urbina 2026, which demonstrates a protective effect on mitochondrial respiration in an organotypic model, adds a third data point that supports the plausibility of the mechanism but does not directly resolve the human clinical disagreement (Diaz-Urbina 2026). The aggregate evidence for Nad Biomarker Effects on cardiometabolic outcomes remains context-dependent and incomplete.","The quantitative findings from this evidence base present a clear picture of biomarker success without functional translation. Wu 2025 reports that NR supplementation successfully increased NAD+ levels within the 5-week intervention period, confirming the biochemical efficacy of the precursor supplementation strategy. However, despite this confirmed increase in the target biomarker, the trial found no significant improvement in cognition compared to the control group. Similarly, null findings were observed for the secondary endpoints, with no significant differences detected between NR and placebo for fatigue, sleep quality, or mood disturbances. These results are detailed in the evidence synthesis (Per-Study Endpoint Evidence), which catalogs the specific p-values and effect sizes for each measured outcome. The dissociation between robust NAD+ elevation and absent cognitive benefit represents a critical finding for the field.","A central tension within the cognitive outcome class is the divergence between biochemical efficacy and functional null findings. Wu 2025 documents that NAD+ levels were successfully elevated, yet this biomarker change did not translate into any measurable cognitive improvement, nor improvement in the broader symptom cluster of fatigue, sleep, and mood. This pattern contrasts with mechanistic human studies and preclinical data that have provided strong biological plausibility for cognitive benefits of NAD+ augmentation. The disagreement is not between competing positive and negative trials but rather between the expected mechanistic outcome and the observed clinical reality. This biomarker-function dissociation raises important questions about whether the 5-week intervention duration was sufficient to manifest cognitive changes, whether the long-COVID cognitive phenotype responds to NAD+ pathways, or whether the cognitive instruments used lacked sensitivity to detect subtle changes."]}